View Older Stories View More Recent Stories

Nov 18, 2022 08:00AM Regen BioPharma, Inc. Progresses Its DuraCAR Therapeutic
Nov 10, 2022 05:47PM Regen BioPharma Developing a Non-Exhaustible CAR-T Cell Therapeutic
Nov 8, 2022 07:00AM Presenting on the Emerging Growth Conference on November 9 Register Now
Nov 2, 2022 11:13AM Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 9, 2022
Oct 26, 2022 10:49AM Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space
Oct 5, 2022 02:17PM Regen BioPharma, Inc. Files Provisional Patent on CAR-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer
Sep 13, 2022 03:09PM Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy
Aug 25, 2022 02:11PM Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors
Aug 11, 2022 03:06PM Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors
Jul 26, 2022 05:14PM Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine
Mar 16, 2022 03:16PM Regen BioPharma, Inc. Responds to Numerous Requests for Updates on its Intellectual Property (IP) Portfolio
Mar 10, 2022 07:00AM Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies
Oct 24, 2016 08:00AM Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, Inc. for treatment of Bone Marrow Suppression Study
Aug 16, 2016 08:00AM Regen BioPharma, Inc. Receives New Preliminary HemaXellerate Clinical Data on Bone Marrow Suppression from Pan Am Cancer Treatment Center
Jul 27, 2016 08:00AM Regen BioPharma, Inc. Files Composition of Matter Patent Application on NR2F6 Modulating Small Molecules
Jun 30, 2016 08:00AM Regen BioPharma, Inc. Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company
Jun 16, 2016 08:00AM Regen BioPharma, Inc.'s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Program
Jun 14, 2016 08:30AM Regen BioPharma, Inc.'s Small Molecule Drug Screening Program Uncovers Activators of NR2F6
Jun 2, 2016 07:00AM Regen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6
Jun 1, 2016 09:23AM Regen BioPharma, Inc. Uplisted to Trade Publicly on OTCQB
May 24, 2016 07:00AM Regen BioPharma, Inc. Files Application to Trade Publicly on OTCQB
May 19, 2016 07:00AM Regen BioPharma, Inc. Announces ucVax: Universal Donor Cancer Cellular Immunotherapy
May 11, 2016 07:00AM Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
May 3, 2016 07:00AM Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients
Apr 28, 2016 07:00AM Regen BioPharma's HemaXellerate Therapy for Treating Aplastic Anemia Licensed for Proof of Concept Study
Apr 21, 2016 07:00AM Regen BioPharma, Inc. Series A Preferred Stock Begins Trading Under the Symbol RGBPP on the OTC PINK
Mar 23, 2016 08:30AM Regen BioPharma, Inc. Submits IND Application to FDA on tCellVax, a Checkpoint Inhibitor for Cancer Therapy
Feb 24, 2016 08:30AM Regen BioPharma, Inc. Completes Preclinical Experimentation for Its siRNA NR2F6 Checkpoint Inhibitor
Feb 17, 2016 08:30AM Regen BioPharma, Inc.'s Immune Checkpoint Inhibitor Found to Stimulate Key Immune System Proteins Interleukin-17 and Interleukin-18
Feb 3, 2016 08:30AM Regen BioPharma, Inc. Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell for Solid Tumors
Jan 26, 2016 08:30AM Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product
Jan 20, 2016 08:30AM Regen BioPharma, Inc. and the National Institutes of Health to Collaborate
Dec 16, 2015 08:30AM Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
Dec 15, 2015 08:30AM Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate
View More Recent Stories View Older Stories